US12674W1099 - Common Stock
CABALETTA BIO INC
NASDAQ:CABA (4/24/2024, 5:45:15 PM)
After market: 12.655 -0.31 (-2.35%)12.96
-0.36 (-2.7%)
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 92 full-time employees. The company went IPO on 2019-10-25. The firm is focused on the discovery and development of engineered T cell for the treatment of patients with autoimmune diseases. Its CABA platform encompasses two approaches: chimeric antigen receptor T cells for autoimmunity (CARTA) and chimeric autoantibody receptor T cells (CAART). Its product candidates include CABA-201, DSG3-CAART, DSG3/1-CAART, MuSK-CAART and PLA2R-CAART. Its lead product candidate, CABA-201, is designed to achieve transient depletion of all CD19-positive B cells following a single infusion, allowing for the elimination disease-causing B cells with subsequent repopulation by naive healthy B cells. Its lead product candidate for the CAART strategy, DSG3-CAART, is designed to enable specific cytotoxicity toward B cells autoreactive to DSG3. Its next PV product candidate, DSG3/1-CAART, is being designed to target DSG3 and/or DSG1 autoreactive B cell receptors on pathogenic B cells that cause mcPV.
CABALETTA BIO INC
2929 Arch Street, Suite 600
PHILADELPHIA PENNSYLVANIA 19104
P: 12677593100
CEO: Steven Nichtberger
Employees: 92
Website: https://www.cabalettabio.com/
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cabaletta Bio (NASDAQ:CABA) just reported results for the fourth quarter of 202...
CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the fourth quarter of 2023.
Here you can normally see the latest stock twits on CABA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: